Startups

Modicus Prime

Modicus Prime develops software for managing AI systems in pharmaceutical manufacturing and other regulated life-sciences operations. Its AI Management System (AIMS) connects quality management systems and data-science tools to centralize AI inventories, intended contexts of use, datasets, model versions, validation evidence, risk assessments, approvals, supplier oversight and lifecycle monitoring. Pharmaceutical manufacturers, contract manufacturers and development organizations use the platform to track AI changes and assemble traceable evidence for internal quality review and audits. The company also provides AI assurance workshops and implementation support. Its earlier mpVision product used computer vision to analyze biologics images, including morphology and contamination-related quality-control workflows. Current AIMS expands the focus to governing internal and supplier-provided AI across the enterprise. The profile describes the software and its intended users without asserting regulator approval, universal compliance certification or independently verified clinical outcomes.

Founded 2020

Team

Arsen GevorgyanTeam member (current title unpublished); Director of Quality in historical own Q&A

David VardanyanTeam member (current title unpublished); Director of Engineering in historical own Q&A

Diana MakovetskaTeam member (affiliation published; exact current title undisclosed)

Edgar KakoyanDirector of Design (historical own leadership Q&A; current status unverified)

Gavin KarrTeam member (affiliation published; exact current title undisclosed)

Jack TopdjianAdvisor and investor (historical own leadership Q&A; current status unverified)

Joel RobertsonVice President of GxP Quality and Compliance

Lawrence ColemanTeam member (affiliation published; exact current title undisclosed)

Mickey LandkofVice President of Revenue

Nikita HorbTeam member (affiliation published; exact current title undisclosed)

Qiao HuangLead Computer Vision Engineer (historical own leadership Q&A; current status unverified)

Roger ChenBoard director (appointment announced July15,2024; current status unverified)

Taylor ChartierFounder and CEO

Vitaliy KucheryaviyChief Technology Officer (historical own leadership Q&A; current status unverified)

Investments

$4M2026-05-06	Frist Cressey Ventures, Silverton Partners, Oncology Ventures
$3M2024-07-15	Silverton Partners, Alumni Ventures

team@apexlogos.ai9 hours ago
The removed pre-seed article (HTTP410) has an indexed primary account of aUSD1.1m round closedDecember31,2022, followed by an undated editorial revision increasing total pre-seed toUSD1.2m after TripleS Ventures. No additional dated cash round is fabricated from this ambiguous revised historical account. Historical financing/backers are retained in the research queue for further primary reconciliation. The company LinkedIn employees carousel lists Ami Nichelson, whose own profile is a travel concierge at an unrelated transportation Modicus; she is excluded. Additional secondary-only names/titles are queued and not asserted as staff. Product governance capability does not constitute FDA/EMA approval or blanket certification.
team@apexlogos.ai9 hours ago
The May6,2026 issuer announces an additionalUSD4.5m financing; the headlineUSD8m refers to cumulative funding. Its exact stage is unknown; conflicting third-party Seed/SeriesA labels are excluded. July15,2024 issuer reportsUSD3.5m series seed. Each manager ticket and exact legal investment vehicle remains unknown. Investor representatives quoted or thanked are not automatically company directors or employees.
team@apexlogos.ai9 hours ago
The own current homepage and June2026 author byline, current supplier-authored CPHI exhibitor material and exact personal profiles support current published affiliations. The older own leadership Q&A has been removed (directHTTP410) but its indexed primary body and exact individual links remain accessible. Historical roles are explicitly qualified; no termination dates or continued employee status are invented. Current personal profiles for David Vardanyan and Arsen Gevorgyan prove affiliation, but do not expose exact current titles; the historical director titles are retained with that qualification. Four additional current personal profiles establish affiliation only; secondary engineering titles are not adopted. Jack Topdjian is an adviser/investor, not an employee. Roger Chen board appointment is an issuer-announced2024 affiliation, not proof of a personal cash ticket or current board tenure.